Carvedilol Tablet, Film Coated
NDC Package 72189-663-90

11-digit billing NDC: 72189066390

Package Information

Carvedilol tablets is 1.1 Heart FailureCarvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions (7.4), Clinical Studies (14.1)].1.2 Left Ventricular Dysfunction following Myocardial InfarctionCarvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies (14.2)].1.3 HypertensionCarvedilol tablets are indicated for the management of essential hypertension [see Clinical Studies (14.3, 14.4)]. This formulation utilizes a tablet, film coated delivery system. Marketed by Direct_rx, this product is identified by NDC 72189-663 and is authorized under FDA application ANDA077614.

Identification & Billing

NDC Package Code
72189-663-90
Package Description
90 TABLET, FILM COATED in 1 BOTTLE
Product Code
11-Digit Billing Format
72189066390
RxNorm Crosswalk
RxCUI: 200033 - carvedilol 25 MG Oral Tablet

Clinical Specifications

Proprietary Name
Carvedilol
Non-Proprietary Name
Carvedilol
Substance Name
Carvedilol
Dosage Form
Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
1.1 Heart FailureCarvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions (7.4), Clinical Studies (14.1)].1.2 Left Ventricular Dysfunction following Myocardial InfarctionCarvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies (14.2)].1.3 HypertensionCarvedilol tablets are indicated for the management of essential hypertension [see Clinical Studies (14.3, 14.4)]. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions (7.2)].

Regulatory & Marketing

Labeler Name
Direct_rx
Product Type
Human Prescription Drug
FDA Application #
ANDA077614
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
03-02-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 72189-663-90 identifies a specific commercial package of 90 tablet, film coated in 1 bottle of Carvedilol, a human prescription drug labeled by Direct_rx. This tablet, film coated is formulated for oral use and contains carvedilol as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Direct_rx on March 02, 2026. The current certification is valid through December 31, 2027.

How is this Direct_rx product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 72189066390. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
72189-663-90
11-Digit CMS (5-4-2)
72189-0663-90

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.